GSK2807 is primarily utilized in biochemical research as a potent and selective inhibitor of BET bromodomain proteins. These proteins play a crucial role in regulating gene expression by binding to acetylated lysines on histones. By inhibiting BET bromodomains, GSK2807 helps researchers study the impact of gene regulation on various cellular processes, including cancer progression, inflammation, and immune responses. Its application is particularly valuable in understanding the molecular mechanisms underlying diseases and in the development of targeted therapies. Additionally, GSK2807 is used in drug discovery efforts to identify and validate new therapeutic targets, making it a significant tool in the field of epigenetics and oncology research.